Literature DB >> 22510144

GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.

L Boero1, M Manavela, T Meroño, P Maidana, L Gómez Rosso, F Brites.   

Abstract

CONTEXT: Acromegaly is characterized by GH excess and insulin resistance. It is not known which of these disorders is responsible for the increased atherogenic risk in these patients.
OBJECTIVE: To analyse the associations of GH and homoeostasis model assessment (HOMA) with biomarkers of cardiovascular disease and to compare the above-mentioned variables between patients with active acromegaly and controls. DESIGN AND
SETTING: This open cross-sectional study was conducted at a University Hospital. PATIENTS: Twenty-two outpatients were compared with sex- and age-matched control subjects. MAIN OUTCOMES: Included clinical features, hormonal status, markers of insulin resistance, lipoprotein profile and biomarkers of cardiovascular disease.
RESULTS: Patients presented higher triglyceride (median [IQR]) (1·2[1·1-1·6] vs 0·9[0·6-1·1] mm, P < 0·05), low-density lipoprotein-cholesterol (LDL-C) (mean ± SD) (3·5 ± 0·9 vs 3·0 ± 0·7mm, P < 0·05), apoB (0·98 ± 0·23 vs 0·77 ± 0·22 g/l, P < 0·05), free fatty acid (0·69 ± 0·2 vs 0·54 ± 0·2 mM, P < 0·05), oxidized-LDL (120 ± 22 vs 85 ± 19 U/l, P < 0·05) and endothelin-1 (0·90 ± 0·23 vs 0·72 ± 0·17 ng/l, P < 0·05) levels, increased cholesteryl ester transfer protein (CETP) activity (179 ± 27 vs 138 ± 30%/ml/h, P < 0·01) and lower C reactive protein (CRP) (0·25[0·1-0·9] vs 0·85[0·4-1·4] mg/l; P < 0·05) levels than control subjects. Vascular cell adhesion molecule (VCAM-1) concentration was not different. By multiple linear regression analyses, HOMA explained the variability of triglycerides (25%), high-density lipoprotein-cholesterol (HDL-C) (30%) and CETP activity (28%), while GH independently predicted LDL-C (18%), oxidized-LDL (40%) and endothelin-1 levels (19%).
CONCLUSIONS: In patients with active acromegaly, GH excess contributes to the development of insulin resistance, and the interaction between both disturbances would be responsible for the appearance of atherogenic pro-oxidative and pro-inflammatory factors. Insulin resistance would be preferably associated with an atherogenic lipoprotein profile and to high CETP activity, while high GH levels would independently predict the increase in LDL-C, ox-LDL and endothelin-1.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510144     DOI: 10.1111/j.1365-2265.2012.04414.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients.

Authors:  Maria Luisa Torre; Giuseppina T Russo; Marta Ragonese; Annalisa Giandalia; Ernesto De Menis; Giorgio Arnaldi; Angela Alibrandi; Carmelo Buda; Giovanni Romanello; Elisabetta L Romeo; Domenico Cucinotta; Francesco Trimarchi; Salvatore Cannavo
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

4.  Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Authors:  Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

5.  Insight into cardiovascular risk factors in patients with acromegaly.

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

Review 6.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 8.  Case Report: A Clinical and Genetic Analysis of Childhood Growth Hormone Deficiency With Familial Hypercholesterolemia.

Authors:  Shengmin Yang; Xiaoan Ke; Hanting Liang; Ran Li; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

9.  No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study).

Authors:  Cheol Ryong Ku; Eun Yeong Choe; Jae Won Hong; Eui Hyun Kim; Se Hee Park; Sun Ho Kim; Eun Jig Lee
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Postoperative Changes in Metabolic Parameters of Patients with Surgically Controlled Acromegaly: Assessment of New Stringent Cure Criteria.

Authors:  Masanori Yonenaga; Shingo Fujio; Mika Habu; Hiroshi Arimura; Takaaki Hiwatari; Shunichi Tanaka; Yasuyuki Kinoshita; Hiroshi Hosoyama; Hirofumi Hirano; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-02-23       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.